title: Withdrawing Benzodiazepines in Patients With Anxiety Disorders.
abstract: The large class of CNS-depressant medications-the benzodiazepines-have been extensively used for over 50 years, anxiety disorders being one of the main indications. A substantial proportion (perhaps up to 20-30 %) of long-term users becomes physically dependent on them. Problems with their use became manifest, and dependence, withdrawal difficulties and abuse were documented by the 1980s. Many such users experience physical and psychological withdrawal symptoms on attempted cessation and may develop clinically troublesome syndromes even during slow tapering. Few studies have been conducted to establish the optimal withdrawal schedules. The usual management comprises slow withdrawal over weeks or months together with psychotherapy of various modalities. Pharmacological aids include antidepressants such as the SSRIs especially if depressive symptoms supervene. Other pharmacological agents such as the benzodiazepine antagonist, flumazenil, and the hormonal agent, melatonin, remain largely experimental. The purpose of this review is to analyse the evidence for the efficacy of the usual withdrawal regimes and the newer agents. It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads.
authors.affiliation: National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neurosciences, King's College London, Denmark Hill, London, SE5 8AF, UK. malcolm.lader@kcl.ac.uk.
authors.forename: Malcolm
authors.initials: M
authors.lastname: Lader
authors.affiliation: National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neurosciences, King's College London, Denmark Hill, London, SE5 8AF, UK.
authors.forename: Andri
authors.initials: A
authors.lastname: Kyriacou
mesh_terms: D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D000069451:Long Term Adverse Effects; D011613:Psychotherapy / Q000379:methods; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000503:physiopathology / Q000523:psychology; D019966:Substance-Related Disorders / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control / Q000523:psychology; D028761:Withholding Treatment
chemical_list: D001569:Benzodiazepines
keywords: Abuse; Benzodiazepines; Circadin; Clinical risks; Dependence; Flumazenil; Withdrawal